Kiadis Pharma Continues to Provide Rhitol to Participating Physicians During Completion of Current Clinical Study

Amsterdam, November 19 (ots/PRNewswire) - Kiadis Pharma announced
today that it has agreed to provide Rhitol during a limited period of
time to requesting physicians participating in the ongoing phase I/II
trial. The Rhitol phase I/II trial is closed for enrolment to treat
new patients and is expected to complete at the end of this year.
Kiadis Pharma anticipates applying for and starting a phase III study
in 2008.

Manja Bouman, CEO Kiadis Pharma commented: "We realised that the
sites participating in the ongoing phase II trial were left without
treatment alternatives following the announcement of the enrolment
closure. The interest these physicians show in using our product for
new patients is very encouraging and we are very pleased that we can
support them by providing Rhitol through special provisions, until
the start of the phase III clinical trial."

The physicians interested in enabling new patients to receive
treatment with Rhitol will obtain regulatory authorization from the
appropriate agency to allow for compassionate use of Rhitol.

Rhitol is under development for patients with severe chronic
steroid refractory Graft versus Host Disease (GvHD) who have
exhausted other treatment options. Chronic GvHD is a condition that
can develop after allogeneic bone marrow transplantation and
resembles an autoimmune disease. The immune cells from the donor
graft cause GvHD by attacking the patient's tissues and organs. There
are two forms of GvHD: acute GvHD appears within 100 days after
transplantation and chronic GvHD begins anytime after that period.
Immune-suppressant drugs, such as steroids, are generally used to
treat chronic GvHD. The disease can become a life-threatening
condition when standard treatment cannot control its progression as
the patient either does not respond to steroid treatment or develops
severe side effects due to their use. Extensive chronic GvHD affects
multiple organs and tissues and results in diminished quality of life
for patients.

For the complete press release, please visit : http://www.kiadis.c
om/news/item/Kiadis_Pharma_continues_to_provide_Rhitol/30?mid=

Certain statements in this announcement are forward-looking
statements. Such statements are based on current expectations and are
subject to a number of risks and uncertainties that could cause
actual results or events to differ materially from those expressed
and implied by the forward-looking statements

ots Originaltext: Kiadis Pharma B.V.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
For more information please contact: Kiadis Pharma B.V., Eefje
Simpelaar, Director Communications, Email: e.simpelaar@kiadis.com,
Tel: +31-208884802, Mob: +31-610829344